AstraZeneca’s Imfinzi strikes immunotherapy’s first win in bile duct cancer, with Merck’s Keytruda behind
AstraZeneca’s Imfinzi strikes immunotherapy’s first win in bile duct cancer, [...]
AstraZeneca’s Imfinzi strikes immunotherapy’s first win in bile duct cancer, [...]
Bristol Myers Squibb, after passing on Acceleron, now eyes Aurinia [...]
Oncopeptides’ shares crash as it pulls Pepaxto from the market, [...]
Pfizer’s COVID-19 vaccine is safe, effective in kids ages 5 [...]
Buckle up AbbVie, Amgen: Biohaven’s oral CGRP drug is gaining [...]
Lilly breached a contract by not paying royalties on big-selling [...]
Sanofi and Regeneron’s Dupixent aces another test, this time in [...]
FDA greenlights Genentech’s eye implant for macular degeneration. Will it [...]
Lupin recalls blood pressure tablets on cancer-causing contamination concerns jkeenan [...]
Regeneron, Novo Nordisk, Lilly and AbbVie stake claims on September’s [...]